Regulation and Remodeling of Membrane Microdomains of Cardiomyocytes During Heart Failure Progression

Update Item Information
Title Regulation and Remodeling of Membrane Microdomains of Cardiomyocytes During Heart Failure Progression
Creator Hong, T.; Shaw, R. M.
Subject Diffusion of Innovation; Heart Failure; Myocardial Ischemia; Myocytes, Cardiac; Adaptor Proteins, Signal Transducing; Membrane Proteins; Membrane Microdomains; Calcium Channels, L-Type; Myocardial Contraction; Biomarkers; Genetic Therapy; Knowledge Discovery
Keyword Cardiovascular; Health and Disease
Description Millions of people worldwide live with heart failure, meaning their hearts can't pump blood through the body as well as they should. That can lead to fatigue and shortness of breath, as the body struggles to get the oxygen it needs. Heart failure is a chronic, progressive condition, and as the heart weakens, everyday activities can become difficult. Some patients eventually require a heart transplant or a surgically implanted device like a defibrillator or a left ventricular assist device to survive. At U of U Health, scientists are learning how the molecular organization of heart cells changes as heart failure progresses, and using that knowledge to pioneer potential gene therapy for heart disease. Associate Professor of Pharmacology and Toxicology TingTing Hong, PhD, and Robin Shaw, MD, PhD, director of the Nora Eccles Harrison Cardiovascular Research and Training Institute have zeroed in on a protein that helps organize molecules and channels on the outer surface of the heart's muscle cells that are critical for coordinating the heart's rhythmic contractions. Levels of that protein, cBIN1, tend to decline with heart failure, worsening the condition. Hong, Shaw and colleagues have found that gene therapy that restores cBIN1 can improve heart function in laboratory animals with heart failure. They've had success using cBIN1 gene therapy to restore function in animals whose hearts have been damaged by a lack of blood flow, similar to the myocardial ischemia patients can experience when an artery is blocked, as well as in non-ischemic cardiac myopathy. Their findings in animal models have paved the way to developing an innovative gene therapy for patients.
Relation is Part of 2023
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date Digital 2025
Date 2023
Type Image
Format image/jpeg
Rights Management Copyright © 2025, University of Utah, All Rights Reserved
Language eng
ARK ark:/87278/s6z4rhgf
References 1.) Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose. Li J, Richmond B, Cluntun AA, Bia R, Walsh MA, Shaw K, Symons JD, Franklin S, Rutter J, Funai K, Shaw RM, Hong T. JCI Insight. 2023 Sep 22;8(18). https://pubmed.ncbi.nlm.nih.gov/37639557/
Press Releases and Media University of Utah Health: "New Gene Therapy Reverses Heart Failure in Large Animal Model" https://healthcare.utah.edu/newsroom/news/2024/12/new-gene-therapy-reverses-heart-failure-large-animal-model; MSN.com https://www.msn.com/en-us/health/other/gene-therapy-reverses-heart-failure-in-new-trials/ar-AA1vBM9c; Yahoo! News https://www.yahoo.com/news/heart-failure-reversed-gene-therapy-142659955.html; Fox News Medicine https://www.foxnews.com/health/heart-failure-reversed-new-gene-therapy-animal-study-unprecedented-recovery; The Telegraph https://www.telegraph.co.uk/news/2024/12/10/university-of-utah-scientists-cure-for-heart-failure-pigs/
Setname ehsl_50disc
ID 2651927
Reference URL https://collections.lib.utah.edu/ark:/87278/s6z4rhgf